SLS Stock Summary and Trading Ideas (Sellas Life Sciences Group | NASDAQ:SLS)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.

As of October 14, 2026, SLS stock price declined to $11.88 with 4,314,154 million shares trading.

SLS has a beta of 0.24, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.00 to the broad based SPY ETF.

SLS has a market cap of $2.40 billion. This is considered a Mid Cap stock.

In the last 3 years, SLS traded as high as $15.88 and as low as $.50.

The top ETF exchange traded funds that SLS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

SLS has outperformed the market in the last year with a price return of +494.0% while the SPY ETF gained +17.2%. However, in the short term, SLS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.9% vs +3.0% return in SPY. But in the last 2 weeks, SLS shares have fared better than the market returning +3.2% compared to SPY +0.7%.

SLS support price is $11.88 and resistance is $12.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.